Shionogi owns 12.5% of Enanta before its initial public offering, while Abbott Labs has 8.38%.
Enanta Pharmaceuticals, a US-based developer of drugs for infectious diseases backed by trade peers Shionogi and Abbott Labs, has filed for a $69m flotation.
Both Shionogi and Abbott market a generic rival to Enanta’s treatment for MRSA infections. Abbott has also paid $92.45m in license fees and milestone payments to Enanta and bought its $12.5m of series G stock at $2.71 per share in November 2006, according to a regulatory filing.
Shionogi owns 12.5% of Enanta before its initial…
